English

KYMERA THERAPEUTICS, INC.

EDGAR

KYMR Quarterly report (10-Q) · filed 2026-10-29

Annual consolidated revenue for 2025: about USD 39.21M, using the latest reported figures. The previous period, 2024, was about USD 47.07M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026 Q3 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-77.9 million USD

2026 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -220818000 USD Source
Operating Cash Flow: -142905000 USD Source

Free cash flow

-78.2 million USD

2026 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -220818000 USD Source
Operating Cash Flow: -142905000 USD Source
Capital Expenditure: 1222000 USD Source
Capital Expenditure: 907000 USD Source

Cash and cash equivalents: 373 million USD 2026-09-30 Source
Exact value

373374000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 85.3 million shares 2026-09-30 Source
Exact value

85325503 shares

Reported share-count change

18.94% · 13.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

71741174 shares · 2025-09-30· Source
85325503 shares · 2026-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

102 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence

Revenue: 39211000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 36341000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 34365000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 65000000 USD · 2026-04-01 – 2026-06-30 Source
Revenue: 0 USD · 2026-07-01 – 2026-09-30 Source

Net income

-349 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence

Net income: -311351000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -224370000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -69234000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -61211000 USD · 2026-04-01 – 2026-06-30 Source
Net income: -131999000 USD · 2026-07-01 – 2026-09-30 Source

Operating cash flow

-288 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence

Operating cash flow: -232891000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -166144000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -88840000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -142905000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -88840000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -220818000 USD · 2026-01-01 – 2026-09-30 Source
Operating cash flow: -142905000 USD · 2026-01-01 – 2026-06-30 Source

Capital expenditure

1.33 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence

Capital expenditure: 1449000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 1343000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 434000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 907000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 434000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 1222000 USD · 2026-01-01 – 2026-09-30 Source
Capital expenditure: 907000 USD · 2026-01-01 – 2026-06-30 Source

Free cash flow

-289 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence

Operating cash flow: -232891000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -166144000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -88840000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -142905000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -88840000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -220818000 USD · 2026-01-01 – 2026-09-30 Source
Operating cash flow: -142905000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 1449000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 1343000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 434000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 907000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 434000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 1222000 USD · 2026-01-01 – 2026-09-30 Source
Capital expenditure: 907000 USD · 2026-01-01 – 2026-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-29.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 7 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2025-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
Total liabilities: 7 of 11 periods available· newest 2025-12-31
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-16.7%

Prior period

USD 47.07 million

2024-01-01 – 2024-12-31
Current period

USD 39.21 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

39211000 − 47072000 = -7861000 USD

47072000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
39211000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · KYMERA THERAPEUTICS, INC. · 2025-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Year-over-year change in Revenue: -7861000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 39211000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#1750352 Filing: 000119312526073395 Input fundies:Revenue: 47072000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#1752005 Filing: 000119312526073395
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 87.49 million

Prior period

−USD 223.86 million

2024-01-01 – 2024-12-31
Current period

−USD 311.35 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-311351000 − -223858000 = -87493000 USD

-223858000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-311351000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · KYMERA THERAPEUTICS, INC. · 2025-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Year-over-year change in Net income: -87493000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -311351000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#3559604 Filing: 000119312526073395 Input fundies:NetIncome: -223858000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#3561352 Filing: 000119312526073395
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 38.39 million

Prior period

−USD 194.5 million

2024-01-01 – 2024-12-31
Current period

−USD 232.89 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-232891000 − -194501000 = -38390000 USD

-194501000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-232891000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · KYMERA THERAPEUTICS, INC. · 2025-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Year-over-year change in Operating cash flow: -38390000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -232891000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2186080 Filing: 000119312526073395 Input fundies:OperatingCashFlow: -194501000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2187970 Filing: 000119312526073395
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-88.7%

Prior period

USD 12.84 million

2024-01-01 – 2024-12-31
Current period

USD 1.45 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

1449000 − 12838000 = -11389000 USD

12838000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1449000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · KYMERA THERAPEUTICS, INC. · 2025-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Year-over-year change in Capital expenditure: -11389000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1449000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2195663 Filing: 000119312526073395 Input fundies:CapitalExpenditure: 12838000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2197429 Filing: 000119312526073395
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 39.21 million 100% of revenue
Operating costs Derived USD 388.61 million 991% of revenue
Operating income −USD 349.4 million −891% of revenue
Tax, interest and other Derived −USD 38.05 million −97% of revenue
Net income −USD 311.35 million −794% of revenue

Cash

Operating cash flow −USD 232.89 million −594% of revenue
Capital expenditure USD 1.45 million 3.7% of revenue
Free cash flow Derived −USD 234.34 million −598% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 1,538% of revenue.
2020 Operating loss: operating costs were 236% of revenue.
2021 Operating loss: operating costs were 238% of revenue.
2022 Operating loss: operating costs were 444% of revenue.
2023 Operating loss: operating costs were 311% of revenue.
2024 Operating loss: operating costs were 656% of revenue.
2025 Operating loss: operating costs were 991% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	2934000	45139000 Derived	-42205000	-959000 Derived	-41246000	17373000 Derived	Source 2019-01-01 – 2019-12-31: 2934000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -42205000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -41246000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 17905000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 532000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	34034000	80338000 Derived	-46304000	-711000 Derived	-45593000	79034000 Derived	Source 2020-01-01 – 2020-12-31: 34034000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -46304000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -45593000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 88130000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 9096000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	72832000	173362000 Derived	-100530000	-313000 Derived	-100217000	-130543000 Derived	Source 2021-01-01 – 2021-12-31: 72832000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -100530000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -100217000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -128946000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1597000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	46826000	208082000 Derived	-161256000	-6448000 Derived	-154808000	-155921000 Derived	Source 2022-01-01 – 2022-12-31: 46826000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -161256000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -154808000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -153085000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 2836000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	78592000	244122000 Derived	-165530000	-18568000 Derived	-146962000	-137306000 Derived	Source 2023-01-01 – 2023-12-31: 78592000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -165530000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -146962000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -102826000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 34480000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	47072000	308707000 Derived	-261635000	-37777000 Derived	-223858000	-207339000 Derived	Source 2024-01-01 – 2024-12-31: 47072000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -261635000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -223858000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -194501000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 12838000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	39211000	388610000 Derived	-349399000	-38048000 Derived	-311351000	-234340000 Derived	Source 2025-01-01 – 2025-12-31: 39211000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -349399000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -311351000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -232891000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 1449000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 39.2M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	2934000	Revenue: 2934000 Open source
20202020-12-31	Revenue	34034000	Revenue: 34034000 Open source
20212021-12-31	Revenue	72832000	Revenue: 72832000 Open source
20222022-12-31	Revenue	46826000	Revenue: 46826000 Open source
20232023-12-31	Revenue	78592000	Revenue: 78592000 Open source
20242024-12-31	Revenue	47072000	Revenue: 47072000 Open source
20252025-12-31	Revenue	39211000	Revenue: 39211000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-16.7% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 2934000 Open source
20202020-12-31	Year over year	1,060%	Revenue: 34034000 Open source Revenue: 2934000 Open source
20212021-12-31	Year over year	114%	Revenue: 72832000 Open source Revenue: 34034000 Open source
20222022-12-31	Year over year	-35.7%	Revenue: 46826000 Open source Revenue: 72832000 Open source
20232023-12-31	Year over year	67.8%	Revenue: 78592000 Open source Revenue: 46826000 Open source
20242024-12-31	Year over year	-40.1%	Revenue: 47072000 Open source Revenue: 78592000 Open source
20252025-12-31	Year over year	-16.7%	Revenue: 39211000 Open source Revenue: 47072000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -891.1% 2025

Net margin -794% 2025

Free cash flow margin -597.6% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-1,438.5%	Operating Income: -42205000 Open source Revenue: 2934000 Open source
20202020-12-31	Operating margin	-136.1%	Operating Income: -46304000 Open source Revenue: 34034000 Open source
20212021-12-31	Operating margin	-138%	Operating Income: -100530000 Open source Revenue: 72832000 Open source
20222022-12-31	Operating margin	-344.4%	Operating Income: -161256000 Open source Revenue: 46826000 Open source
20232023-12-31	Operating margin	-210.6%	Operating Income: -165530000 Open source Revenue: 78592000 Open source
20242024-12-31	Operating margin	-555.8%	Operating Income: -261635000 Open source Revenue: 47072000 Open source
20252025-12-31	Operating margin	-891.1%	Operating Income: -349399000 Open source Revenue: 39211000 Open source
20192019-12-31	Net margin	-1,405.8%	Net Income: -41246000 Open source Revenue: 2934000 Open source
20202020-12-31	Net margin	-134%	Net Income: -45593000 Open source Revenue: 34034000 Open source
20212021-12-31	Net margin	-137.6%	Net Income: -100217000 Open source Revenue: 72832000 Open source
20222022-12-31	Net margin	-330.6%	Net Income: -154808000 Open source Revenue: 46826000 Open source
20232023-12-31	Net margin	-187%	Net Income: -146962000 Open source Revenue: 78592000 Open source
20242024-12-31	Net margin	-475.6%	Net Income: -223858000 Open source Revenue: 47072000 Open source
20252025-12-31	Net margin	-794%	Net Income: -311351000 Open source Revenue: 39211000 Open source
20192019-12-31	Free cash flow margin	592.1%	Revenue: 2934000 Open source Operating Cash Flow: 17905000 Open source Capital Expenditure: 532000 Open source
20202020-12-31	Free cash flow margin	232.2%	Revenue: 34034000 Open source Operating Cash Flow: 88130000 Open source Capital Expenditure: 9096000 Open source
20212021-12-31	Free cash flow margin	-179.2%	Revenue: 72832000 Open source Operating Cash Flow: -128946000 Open source Capital Expenditure: 1597000 Open source
20222022-12-31	Free cash flow margin	-333%	Revenue: 46826000 Open source Operating Cash Flow: -153085000 Open source Capital Expenditure: 2836000 Open source
20232023-12-31	Free cash flow margin	-174.7%	Revenue: 78592000 Open source Operating Cash Flow: -102826000 Open source Capital Expenditure: 34480000 Open source
20242024-12-31	Free cash flow margin	-440.5%	Revenue: 47072000 Open source Operating Cash Flow: -194501000 Open source Capital Expenditure: 12838000 Open source
20252025-12-31	Free cash flow margin	-597.6%	Revenue: 39211000 Open source Operating Cash Flow: -232891000 Open source Capital Expenditure: 1449000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -232.9M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	17905000	Operating Cash Flow: 17905000 Open source
20202020-12-31	Operating cash flow	88130000	Operating Cash Flow: 88130000 Open source
20212021-12-31	Operating cash flow	-128946000	Operating Cash Flow: -128946000 Open source
20222022-12-31	Operating cash flow	-153085000	Operating Cash Flow: -153085000 Open source
20232023-12-31	Operating cash flow	-102826000	Operating Cash Flow: -102826000 Open source
20242024-12-31	Operating cash flow	-194501000	Operating Cash Flow: -194501000 Open source
20252025-12-31	Operating cash flow	-232891000	Operating Cash Flow: -232891000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -234.3M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	17373000	Operating Cash Flow: 17905000 Open source Capital Expenditure: 532000 Open source
20202020-12-31	Free cash flow	79034000	Operating Cash Flow: 88130000 Open source Capital Expenditure: 9096000 Open source
20212021-12-31	Free cash flow	-130543000	Operating Cash Flow: -128946000 Open source Capital Expenditure: 1597000 Open source
20222022-12-31	Free cash flow	-155921000	Operating Cash Flow: -153085000 Open source Capital Expenditure: 2836000 Open source
20232023-12-31	Free cash flow	-137306000	Operating Cash Flow: -102826000 Open source Capital Expenditure: 34480000 Open source
20242024-12-31	Free cash flow	-207339000	Operating Cash Flow: -194501000 Open source Capital Expenditure: 12838000 Open source
20252025-12-31	Free cash flow	-234340000	Operating Cash Flow: -232891000 Open source Capital Expenditure: 1449000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

9.4% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	70.3%	Total Liabilities: 82028000 Open source Total Assets: 116702000 Open source
20202020-12-31	Liabilities / assets	41.7%	Total Liabilities: 203287000 Open source Total Assets: 487175000 Open source
20212021-12-31	Liabilities / assets	24.1%	Total Liabilities: 146267000 Open source Total Assets: 605905000 Open source
20222022-12-31	Liabilities / assets	18.7%	Total Liabilities: 112983000 Open source Total Assets: 603134000 Open source
20232023-12-31	Liabilities / assets	31.4%	Total Liabilities: 180788000 Open source Total Assets: 575759000 Open source
20242024-12-31	Liabilities / assets	14.6%	Total Liabilities: 142416000 Open source Total Assets: 978035000 Open source
20252025-12-31	Liabilities / assets	9.4%	Total Liabilities: 163148000 Open source Total Assets: 1742812000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

10.47× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	2.69×	Current Assets: 92845000 Open source Current Liabilities: 34570000 Open source
20202020-12-31	Current assets / current liabilities	2.73×	Current Assets: 302339000 Open source Current Liabilities: 110617000 Open source
20212021-12-31	Current assets / current liabilities	4.88×	Current Assets: 451273000 Open source Current Liabilities: 92542000 Open source
20222022-12-31	Current assets / current liabilities	5.88×	Current Assets: 419416000 Open source Current Liabilities: 71343000 Open source
20232023-12-31	Current assets / current liabilities	4.73×	Current Assets: 405317000 Open source Current Liabilities: 85691000 Open source
20242024-12-31	Current assets / current liabilities	7.53×	Current Assets: 510268000 Open source Current Liabilities: 67767000 Open source
20252025-12-31	Current assets / current liabilities	10.47×	Current Assets: 871214000 Open source Current Liabilities: 83212000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 41.25 million Exact value Exact value: -41246000 USD 2019-01-01 – 2019-12-31: -41246000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KYMERA THERAPEUTICS, INC. · 2019-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Net Income: -41246000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -41246000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017022001860/kymr-20211231.htm#4411648 Filing: 000095017022001860 The citation records this snapshot. The page link may show a newer release later.	USD 17.91 million Exact value Exact value: 17905000 USD 2019-01-01 – 2019-12-31: 17905000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KYMERA THERAPEUTICS, INC. · 2019-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Operating Cash Flow: 17905000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 17905000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017022001860/kymr-20211231.htm#3074458 Filing: 000095017022001860 The citation records this snapshot. The page link may show a newer release later.	USD 532,000 Exact value Exact value: 532000 USD 2019-01-01 – 2019-12-31: 532000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KYMERA THERAPEUTICS, INC. · 2019-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Capital Expenditure: 532000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 532000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017022001860/kymr-20211231.htm#3084563 Filing: 000095017022001860 The citation records this snapshot. The page link may show a newer release later.	USD 17.37 million Calculation and evidence 17905000 − 532000 USD Exact free cash flow: 17373000 USD 2019-01-01 – 2019-12-31: 17905000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 532000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KYMERA THERAPEUTICS, INC. · 2019-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Free cash flow: 17373000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 17905000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017022001860/kymr-20211231.htm#3074458 Filing: 000095017022001860 Input fundies:CapitalExpenditure: 532000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017022001860/kymr-20211231.htm#3084563 Filing: 000095017022001860 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 45.59 million Exact value Exact value: -45593000 USD 2020-01-01 – 2020-12-31: -45593000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KYMERA THERAPEUTICS, INC. · 2020-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Net Income: -45593000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -45593000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017023003935/kymr-20221231.htm#4818932 Filing: 000095017023003935 The citation records this snapshot. The page link may show a newer release later.	USD 88.13 million Exact value Exact value: 88130000 USD 2020-01-01 – 2020-12-31: 88130000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KYMERA THERAPEUTICS, INC. · 2020-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Operating Cash Flow: 88130000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 88130000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017023003935/kymr-20221231.htm#3311677 Filing: 000095017023003935 The citation records this snapshot. The page link may show a newer release later.	USD 9.1 million Exact value Exact value: 9096000 USD 2020-01-01 – 2020-12-31: 9096000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KYMERA THERAPEUTICS, INC. · 2020-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Capital Expenditure: 9096000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9096000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017023003935/kymr-20221231.htm#3322917 Filing: 000095017023003935 The citation records this snapshot. The page link may show a newer release later.	USD 79.03 million Calculation and evidence 88130000 − 9096000 USD Exact free cash flow: 79034000 USD 2020-01-01 – 2020-12-31: 88130000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 9096000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KYMERA THERAPEUTICS, INC. · 2020-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Free cash flow: 79034000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 88130000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017023003935/kymr-20221231.htm#3311677 Filing: 000095017023003935 Input fundies:CapitalExpenditure: 9096000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017023003935/kymr-20221231.htm#3322917 Filing: 000095017023003935 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 100.22 million Exact value Exact value: -100217000 USD 2021-01-01 – 2021-12-31: -100217000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KYMERA THERAPEUTICS, INC. · 2021-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Net Income: -100217000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -100217000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017024018414/kymr-20231231.htm#2958596 Filing: 000095017024018414 The citation records this snapshot. The page link may show a newer release later.	−USD 128.95 million Exact value Exact value: -128946000 USD 2021-01-01 – 2021-12-31: -128946000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KYMERA THERAPEUTICS, INC. · 2021-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Operating Cash Flow: -128946000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -128946000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017024018414/kymr-20231231.htm#1992288 Filing: 000095017024018414 The citation records this snapshot. The page link may show a newer release later.	USD 1.6 million Exact value Exact value: 1597000 USD 2021-01-01 – 2021-12-31: 1597000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KYMERA THERAPEUTICS, INC. · 2021-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Capital Expenditure: 1597000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1597000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017024018414/kymr-20231231.htm#1999157 Filing: 000095017024018414 The citation records this snapshot. The page link may show a newer release later.	−USD 130.54 million Calculation and evidence -128946000 − 1597000 USD Exact free cash flow: -130543000 USD 2021-01-01 – 2021-12-31: -128946000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1597000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KYMERA THERAPEUTICS, INC. · 2021-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Free cash flow: -130543000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -128946000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017024018414/kymr-20231231.htm#1992288 Filing: 000095017024018414 Input fundies:CapitalExpenditure: 1597000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017024018414/kymr-20231231.htm#1999157 Filing: 000095017024018414 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 154.81 million Exact value Exact value: -154808000 USD 2022-01-01 – 2022-12-31: -154808000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KYMERA THERAPEUTICS, INC. · 2022-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Net Income: -154808000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -154808000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017025028355/kymr-20241231.htm#3273028 Filing: 000095017025028355 The citation records this snapshot. The page link may show a newer release later.	−USD 153.09 million Exact value Exact value: -153085000 USD 2022-01-01 – 2022-12-31: -153085000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KYMERA THERAPEUTICS, INC. · 2022-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Operating Cash Flow: -153085000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -153085000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017025028355/kymr-20241231.htm#2085873 Filing: 000095017025028355 The citation records this snapshot. The page link may show a newer release later.	USD 2.84 million Exact value Exact value: 2836000 USD 2022-01-01 – 2022-12-31: 2836000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KYMERA THERAPEUTICS, INC. · 2022-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Capital Expenditure: 2836000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2836000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017025028355/kymr-20241231.htm#2094568 Filing: 000095017025028355 The citation records this snapshot. The page link may show a newer release later.	−USD 155.92 million Calculation and evidence -153085000 − 2836000 USD Exact free cash flow: -155921000 USD 2022-01-01 – 2022-12-31: -153085000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 2836000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KYMERA THERAPEUTICS, INC. · 2022-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Free cash flow: -155921000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -153085000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017025028355/kymr-20241231.htm#2085873 Filing: 000095017025028355 Input fundies:CapitalExpenditure: 2836000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000095017025028355/kymr-20241231.htm#2094568 Filing: 000095017025028355 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 146.96 million Exact value Exact value: -146962000 USD 2023-01-01 – 2023-12-31: -146962000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KYMERA THERAPEUTICS, INC. · 2023-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Net Income: -146962000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -146962000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#3563103 Filing: 000119312526073395 The citation records this snapshot. The page link may show a newer release later.	−USD 102.83 million Exact value Exact value: -102826000 USD 2023-01-01 – 2023-12-31: -102826000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KYMERA THERAPEUTICS, INC. · 2023-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Operating Cash Flow: -102826000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -102826000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2189860 Filing: 000119312526073395 The citation records this snapshot. The page link may show a newer release later.	USD 34.48 million Exact value Exact value: 34480000 USD 2023-01-01 – 2023-12-31: 34480000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KYMERA THERAPEUTICS, INC. · 2023-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Capital Expenditure: 34480000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 34480000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2199196 Filing: 000119312526073395 The citation records this snapshot. The page link may show a newer release later.	−USD 137.31 million Calculation and evidence -102826000 − 34480000 USD Exact free cash flow: -137306000 USD 2023-01-01 – 2023-12-31: -102826000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 34480000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KYMERA THERAPEUTICS, INC. · 2023-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Free cash flow: -137306000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -102826000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2189860 Filing: 000119312526073395 Input fundies:CapitalExpenditure: 34480000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2199196 Filing: 000119312526073395 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 223.86 million Exact value Exact value: -223858000 USD 2024-01-01 – 2024-12-31: -223858000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KYMERA THERAPEUTICS, INC. · 2024-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Net Income: -223858000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -223858000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#3561352 Filing: 000119312526073395 The citation records this snapshot. The page link may show a newer release later.	−USD 194.5 million Exact value Exact value: -194501000 USD 2024-01-01 – 2024-12-31: -194501000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KYMERA THERAPEUTICS, INC. · 2024-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Operating Cash Flow: -194501000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -194501000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2187970 Filing: 000119312526073395 The citation records this snapshot. The page link may show a newer release later.	USD 12.84 million Exact value Exact value: 12838000 USD 2024-01-01 – 2024-12-31: 12838000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KYMERA THERAPEUTICS, INC. · 2024-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Capital Expenditure: 12838000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12838000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2197429 Filing: 000119312526073395 The citation records this snapshot. The page link may show a newer release later.	−USD 207.34 million Calculation and evidence -194501000 − 12838000 USD Exact free cash flow: -207339000 USD 2024-01-01 – 2024-12-31: -194501000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 12838000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KYMERA THERAPEUTICS, INC. · 2024-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Free cash flow: -207339000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -194501000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2187970 Filing: 000119312526073395 Input fundies:CapitalExpenditure: 12838000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2197429 Filing: 000119312526073395 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 311.35 million Exact value Exact value: -311351000 USD 2025-01-01 – 2025-12-31: -311351000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KYMERA THERAPEUTICS, INC. · 2025-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Net Income: -311351000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -311351000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#3559604 Filing: 000119312526073395 The citation records this snapshot. The page link may show a newer release later.	−USD 232.89 million Exact value Exact value: -232891000 USD 2025-01-01 – 2025-12-31: -232891000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KYMERA THERAPEUTICS, INC. · 2025-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Operating Cash Flow: -232891000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -232891000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2186080 Filing: 000119312526073395 The citation records this snapshot. The page link may show a newer release later.	USD 1.45 million Exact value Exact value: 1449000 USD 2025-01-01 – 2025-12-31: 1449000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KYMERA THERAPEUTICS, INC. · 2025-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Capital Expenditure: 1449000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1449000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2195663 Filing: 000119312526073395 The citation records this snapshot. The page link may show a newer release later.	−USD 234.34 million Calculation and evidence -232891000 − 1449000 USD Exact free cash flow: -234340000 USD 2025-01-01 – 2025-12-31: -232891000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 1449000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KYMERA THERAPEUTICS, INC. · 2025-12-31 KYMERA THERAPEUTICS, INC. (edgar:1815442) Free cash flow: -234340000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:04:10Z Snapshot: 7b80ada0a64bda4b36a547d127db6e6cea0aba42e63e54ac8b35ad3f4b537899 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1815442?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -232891000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2186080 Filing: 000119312526073395 Input fundies:CapitalExpenditure: 1449000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/kymr-20251231.htm#2195663 Filing: 000119312526073395 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

37 filings · 1,810 latest values · 1,810 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001815442, 1815442, KYMR, edgar:1815442

Also known as KYMERA THERAPEUTICS, INC., Kymera Therapeutics, Inc.

KYMERA THERAPEUTICS, INC.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation